Printer Friendly

SHAREHOLDERS OF MARION MERRELL DOW ELECT DIRECTORS, HEAR PERFORMANCE UPDATE

 SHAREHOLDERS OF MARION MERRELL DOW ELECT DIRECTORS,
 HEAR PERFORMANCE UPDATE
 KANSAS CITY, Mo., May 19 /PRNewswire/ -- Shareholders of Marion Merrell Dow Inc. (NYSE: MKC) today elected 14 individuals to the board of directors, including three new members, heard updates on the company's growth and transacted other business at the company's annual meeting.
 "We had an outstanding year in 1991, and we're off to another great start in 1992," said Joseph G. Temple, Jr., chairman of the board. "Marion Merrell Dow has the most productive associates in the U.S. pharmaceutical industry -- No. 1 in sales per associate and No. 1 in net income per associate. We also rank in the top tier of the industry in other financial measures, such as growth in earnings, sales and dividends.
 "With this high level of productivity," Temple added, "we're making the best of the new products we have recently brought to market, and we're developing exciting new medications that will improve the lives of millions of people in the years ahead."
 Fred W. Lyons, Jr., president and chief executive officer, told stockholders that the company's strategies for 1992 to 1995 are to continue to increase sales of its major product lines, switch some drugs, notably its Seldane(R) antiallergy product, from prescription to over-the-counter sales, promote the company's international growth and accelerate research and development of new drugs that meet major patient needs.
 In a review of Marion Merrell Dow's new-product opportunities, Lyons said the company is focusing its efforts on 40-50 drugs to treat a number of serious medical problems. For example, he said, the company is developing products to treat conditions such as drug- resistant infections, epilepsy, asthma and rheumatoid arthritis, diabetic complications and Alzheimer's disease.
 David B. Sharrock, executive vice president and chief operating officer, said Marion Merrell Dow's 16 percent sales growth in 1991 and 21 percent sales growth in the first quarter of 1992 came primarily from growth in unit volume, not from price increases.
 Sharrock said the company is sensitive to the problem of increasing health care costs and noted that Marion Merrell Dow's policy is to hold overall increases in its prescription drug prices to no more than the annual rate of inflation -- expected to be less than 4 percent in 1992. He also said the company has broadened its voluntary discounts to public health clinics and is expanding its program of providing pharmaceuticals at no charge to indigent patients, as part of efforts to improve access to the health care system for those who otherwise would be unable to afford drug therapy.
 The stockholders today elected three new directors to one-year terms: R. Malcolm Barbour, the company's senior vice president, Strategic Development; Paul G. Rogers, a partner in the Washington law firm of Hogan & Hartson; and William S. Stavropoulos, Ph.D., senior vice president of The Dow Chemical Co. and president of Dow U.S.A. Barbour's election represents an effort to broaden participation of the company's executives on the board through a rotation system. The board's intention is that each year one senior management associate will serve a one-year term as a director. The executive then will serve one additional year as an advisory director, and another executive will be nominated to the board. The advisory director for the coming year will be Walter M. Lovenberg, Ph.D., executive vice president of the company and president of the Marion Merrell Dow Research Institute.
 Also elected to one-year terms were Ewing M. Kauffman, chairman emeritus; Mr. Temple; Mr. Lyons; John A. Biles, Ph.D., dean of the School of Pharmacy, University of Southern California; Frank L. Douglas, Ph.D., M.D., executive vice president, Research and Development; Enrique C. Falla, executive vice president and chief financial officer, The Dow Chemical Co.; James H. Gardner, Ph.D., professor of management, Graduate School of Business, University of Utah; Edward W. Mehrer, executive vice president, chief financial and administrative officer; Frank P. Popoff, president and chief executive officer of The Dow Chemical Co.; Mr. Sharrock; and James B. Wyngaarden, M.D., foreign secretary of the National Academy of Sciences.
 Shareholders also approved the company's 1992 Incentive Compensation Plan, which is intended to encourage stock ownership by all of the company's associates and to provide incentives to enhance the company's continued growth.
 -0- 5/19/92
 /CONTACT: David M. Thompson or Richard M. Johnson both of Marion Merrell Dow, 816-966-4000/
 (MKC) CO: Marion Merrell Dow Inc. ST: Missouri IN: MTC SU:


MC-TS -- DV013 -- 2086 05/19/92 17:51 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1992
Words:751
Previous Article:ITF EXPRESSES SUPPORT FOR CANADIAN FLIGHT ATTENDANTS DURING WASHINGTON MEETING
Next Article:NEW YORK STOCK EXCHANGE CLOSING, TUESDAY, MAY 19 /PRN/
Topics:


Related Articles
MARION MERRELL DOW PROPOSES THREE NEW MEMBERS TO JOIN ITS BOARD OF DIRECTORS
MARION MERRELL DOW BOARD OF DIRECTORS NOMINATES JUDITH A. HEMBERGER, PH.D., TO BOARD
MARION MERRELL DOW SIMPLIFIES GLOBAL BUSINESS STRUCTURE, NAMES LEADERS
MARION MERRELL DOW INC. BOARD OF DIRECTORS NOMINATES PETER W. LADELL TO BOARD
MARION MERRELL DOW INC. HOLDS ANNUAL MEETING, LONG-TERM FUTURE IS MAIN TOPIC OF DISCUSSION
KEITH R. MCKENNON NAMED TO BOARD OF DIRECTORS OF MARION MERRELL DOW INC.
MARION MERRELL DOW INC. BOARD OF DIRECTORS NOMINATES CHRISTIAN M. ERTLE TO BOARD
JUDITH A. HEMBERGER, PH.D., TO LEAD DRUG REGULATORY AFFAIRS FOR HOECHST MARION ROUSSEL
PETER W. LADELL TO LEAD NORTH AMERICAN UNIT OF HOECHST MARION ROUSSEL
FRANK L. DOUGLAS, PH.D., M.D., TO LEAD RESEARCH FOR HOECHST MARION ROUSSEL

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters